Asian Liver Center

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Retrieved on: 
Monday, November 6, 2023
Avalon, Modified vaccinia Ankara, Autoimmunity, American Association for Cancer Research, Hepatology, Vaccine, Liver, Immunogenicity, LDN, PD-1, University, CHB, Research, Barinthus, Immune system, COVID-19, Efficacy, MVA, Hepatitis, Repeat, Hepatitis B, Infection, Cancer, HBsAg, Patient, Asian Liver Center, HBV, AASLD, Pharmaceutical industry, Oxford–AstraZeneca COVID-19 vaccine, Safety

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023. As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com.

Key Points: 
  • The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.
  • The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023.
  • As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com .
  • “Today the company is focused on the development of novel T cell immunotherapeutic candidates, which evolved out of that initial vaccine research.

One GI Continues Eastern US Expansion

Retrieved on: 
Wednesday, November 30, 2022
CSL, Growth, App, Gastroenterology, Multimedia, Partnership, Physician, Patient, K&L Gates, MD, GI, Stomach, Asian Liver Center, Asset management

Formed inApril 2020, One GI is comprised of leading gastroenterology practices throughoutthe Eastern US.

Key Points: 
  • Formed inApril 2020, One GI is comprised of leading gastroenterology practices throughoutthe Eastern US.
  • Goodwin Procterserved as exclusive legal counsel to One GI, and Alvarez & Marsal Transaction Advisory Group provided key diligence.
  • One GI is a gastroenterology healthcare services organization that partners with GI physicians to help them manage, optimize, and grow their practices.
  • One GI provides critical business services to physicians so they can focus on what they do best: providing excellent care to patients.

Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334

Retrieved on: 
Monday, November 14, 2022
Clinical trial, Institute of Liver and Biliary Sciences, Degenerative disease, HBV, Liver, American Association for the Study of Liver Diseases, Hepatitis B virus, DNA, Liver transplantation, Asian Liver Center, Chhattisgarh Special Public Security Act, Pharmacokinetics, Safety, Chronic liver disease, Annual report, Therapy, COVID-19, Sumathi Best Television Current Reporting Award, CccDNA, SAN, AASLD, AES, Assembly, Patient, Pharmaceutical industry, Vaccine

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334 (4334).

Key Points: 
  • 4334 is an investigational next-generation core inhibitor that is optimized for significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production versus first-generation core inhibitors.
  • In preclinical research, 4334 has demonstrated sub-nanomolar potency against pgRNA encapsidation and 2-3 nanomolar potency against cccDNA formation.
  • Chronic HBV infection is a debilitating disease of the liver that is estimated to impact approximately 296 million people worldwide.
  • The Phase 1a clinical trial is a randomized, blinded and placebo-controlled study that will evaluate the safety, tolerability and pharmacokinetics of 4334 following single ascending dose and multiple ascending dose administration in healthy participants.

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, November 10, 2022
AstraZeneca, Private Securities Litigation Reform Act, IV, IND, Nivolumab, Vaccine, U.S. Securities and Exchange Commission, ChAdOx1, MVA, Tumor microenvironment, Research, AASLD, HPV, G&A, Șaeș, SEC, Annual report, Degenerative disease, University, Vaccitech, Company, Vaccination, Cancer, Asian Liver Center, CHB, Clinical trial, OUI, Patient, Immune system, Autoimmunity, Ulsan College, Drug discovery, Security (finance), Insurance, COVID-19, Pharmaceutical industry, Food delivery, HBsAg, Gastroenterology, Cell

An Investigational New Drug (IND) application submission is expected during the first half of 2023 for HPV related cancer.

Key Points: 
  • An Investigational New Drug (IND) application submission is expected during the first half of 2023 for HPV related cancer.
  • On September 20, 2022, we announced the promotion of Gemma Brown to Chief Financial Officer.
  • Vaccitech is entitled to receive a share of all milestone and royalty income received by OUI from AstraZeneca related to Vaxzevria.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Retrieved on: 
Monday, November 7, 2022
University of Ulsan College of Medicine, Liver disease, Patient, Immune tolerance, Ulsan College, IB Group 2 subjects, Liver, Nivolumab, GLOBE, Asian Liver Center, Modified vaccinia Ankara, Safety, Department, Poster, Group 3, Group 1, University, AASLD, Group 2, HBV, MVA, Vaccine, NASDAQ, Hepatitis, Infection, Disease, Antigen, Degenerative disease, American Association, Association, Cancer, Group 4, OXFORD, Pharmaceutical industry, Vaccitech, HBsAg

OXFORD, United Kingdom, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from its HBV002 trial (NCT04778904). The data will be presented as a poster at the 2022 American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® by Dr. Young-Suk Lim, Professor of the Department of Gastroenterology and the Liver Center, Asian Medical Center, University of Ulsan College of Medicine, Korea.

Key Points: 
  • VTP-300 induced sustained reductions of hepatitis B surface antigen in people with chronic hepatitis B during ongoing, fully enrolled Phase 1b/2a trial.
  • Vaccitechs updated interim analysis includes data from the fully-enrolled trial of 55 patients with chronic hepatitis B (HBV) with at least three months of follow-up.
  • It shows that VTP-300 induced meaningful, sustained reductions of HBV surface antigen (HBsAg) in people with chronic HBV.
  • Enrollment in the HBV002 trial is complete, with a final update expected early in the second quarter of 2023.

Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  

Retrieved on: 
Wednesday, November 3, 2021
Fibrosis, Beth Israel Deaconess Medical Center, Liver disease, AASLD, University, Harvard Medical School, MPS, University of Florida, SGLT2, Association, Institute of Liver and Biliary Sciences, Type 2 diabetes, NAFLD, Metabolism, CET, Patient, Control, American Association for the Study of Liver Diseases, Asian Liver Center, Lists of people executed in the United States, Internet, PAN, Mucopolysaccharidosis, Clinical trial, Webcast, CEO, Hepatology, Program, T2D, Liver, News, Fatty liver disease, American Association, NASH, Euronext Paris, Q&A, Division, University Medical Center, CAP, Associate, Agenda, Fungiculture, Pharmaceutical industry, Management, Hospital, Dietary supplement

Following an introduction from Frdric Cren, Chairman, CEO and cofounder of Inventiva and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, the event will consist of the presentation of five scientific abstracts presented at AASLD The Liver Meeting 2021, as well as four presentations focused on the latest news around the development of lanifibranor and various aspects related to NASH.

Key Points: 
  • Following an introduction from Frdric Cren, Chairman, CEO and cofounder of Inventiva and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, the event will consist of the presentation of five scientific abstracts presented at AASLD The Liver Meeting 2021, as well as four presentations focused on the latest news around the development of lanifibranor and various aspects related to NASH.
  • As part of the program, there will be dedicated Q&A sessions.
  • The Agenda will be as follows:
    Speakers: Frederic Cren, CEO and cofounder of Inventiva Pharma and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva Pharma
    Speaker: Prof. Nezam Afdhal, Harvard Medical School in Boston, Massachusetts and Chief of Hepatology and Director of the Liver Center at Beth Israel Deaconess Medical Center
    Abstract #1: Lanifibranor treatment improves hepatic steatosis in patients with NASH, evaluated by histological grading and Controlled Attenuation Parameter (CAP)."
  • Speaker: Prof. Jorn Schattenberg, Director of the Metabolic Liver Research Program at the University Medical Center of Mainz, Germany
    Abstract #4: "Treatment response to the PAN-PPAR agonist lanifibranor in the NATIVE study: NASH resolution and fibrosis improvement are correlated."

Liver Disease Patients Struggle with Healthy Habits During the Covid-19 Pandemic, Data Show

Retrieved on: 
Thursday, September 16, 2021
Snack, Fatty liver disease, Alcoholic hepatitis, Water, Liver, SCLC, Liver disease, American Association, GI, Patient, Meal, COVID-19, Habit, Liver transplantation, Disease, HIV disease progression rates, Association, Physician, Institute of Liver and Biliary Sciences, Asian Liver Center, Sodium, Diet, Vegetable, Awareness, Health, Dietary supplement, Animal

However, when the Covid-19 pandemic disrupted our daily lives, liver disease patients experienced a downturn in their healthy habits.

Key Points: 
  • However, when the Covid-19 pandemic disrupted our daily lives, liver disease patients experienced a downturn in their healthy habits.
  • Amsetys analysis shows that the diet and lifestyle habits of liver disease patients have significantly worsened since the beginning of the Covid-19 pandemic.
  • To understand the impact of the Covid-19 pandemic on the dietary and lifestyle habits of liver disease patients, Amsetythe first liver health nutrition company in the U.S.has analyzed the data of the Liver Health Score.
  • Long-term disruptions in healthy habits can cause disease progression and a surge of liver disease cases overall across the country.

Orphan Drug Development to Target Increasing Incidence of Liver Cancer

Retrieved on: 
Wednesday, July 22, 2020
Cancer, Medical specialties, Clinical medicine, Hepatology, RTT, Infectious causes of cancer, Carcinogenesis, Epidemiology of cancer, Hepatocellular carcinoma, Liver cancer, Sirtex, Asian Liver Center

Thus, increasing research activities in the development of the novel drug and therapeutic systems are anticipated to propel the global liver cancer treatment market.

Key Points: 
  • Thus, increasing research activities in the development of the novel drug and therapeutic systems are anticipated to propel the global liver cancer treatment market.
  • Hepatocellular carcinoma, or primary liver cancer, tends to grow and expand at a fast rate if it is not detected early.
  • The report continued : "Factors such as rising incidence of liver cancer and growing research activities for developing novel treatments coupled with increasing government funding for the cancer treatment research are driving the global liver cancer treatment market.
  • Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time.

Orphan Drug Development to Target Increasing Incidence of Liver Cancer

Retrieved on: 
Wednesday, July 22, 2020
Cancer, Medical specialties, Clinical medicine, Hepatology, RTT, Infectious causes of cancer, Carcinogenesis, Epidemiology of cancer, Hepatocellular carcinoma, Liver cancer, Sirtex, Asian Liver Center

Thus, increasing research activities in the development of the novel drug and therapeutic systems are anticipated to propel the global liver cancer treatment market.

Key Points: 
  • Thus, increasing research activities in the development of the novel drug and therapeutic systems are anticipated to propel the global liver cancer treatment market.
  • Hepatocellular carcinoma, or primary liver cancer, tends to grow and expand at a fast rate if it is not detected early.
  • The report continued : "Factors such as rising incidence of liver cancer and growing research activities for developing novel treatments coupled with increasing government funding for the cancer treatment research are driving the global liver cancer treatment market.
  • Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time.

Outcome Health Announces Partnership with American Liver Foundation to Promote Updated Screening Recommendations for Hepatitis C

Retrieved on: 
Tuesday, August 14, 2018
Medicine, Healthcare-associated infections, Health, Immunology, Infectious causes of cancer, Hepatitis, RTT, American Liver Foundation, Hepatology, Asian Liver Center, The British Liver Trust

CHICAGO, Aug. 14, 2018 /PRNewswire/ --Outcome Health, a healthcare innovation company focused on evolving the point-of-care market, today announced a partnership with the American Liver Foundation (ALF), a non-profit organization that promotes liver health and disease prevention, to raise awareness of liver disease, specifically hepatitis C. The two organizations will launch a nationwide campaign to promote the recently updated hepatitis C screening recommendations to patients in physician offices.

Key Points: 
  • CHICAGO, Aug. 14, 2018 /PRNewswire/ --Outcome Health, a healthcare innovation company focused on evolving the point-of-care market, today announced a partnership with the American Liver Foundation (ALF), a non-profit organization that promotes liver health and disease prevention, to raise awareness of liver disease, specifically hepatitis C. The two organizations will launch a nationwide campaign to promote the recently updated hepatitis C screening recommendations to patients in physician offices.
  • The educational information in this campaign includes the updated screening guidelines along with basic information about hepatitis and other liver diseases.
  • "Fifty-five million people across the world don't know that they are living with hepatitis C," said Matt McNally, Chief Executive Officer at Outcome Health.
  • Founded in 1976, the American Liver Foundation (ALF) is the nation's largest patient advocacy organization for people with liver disease.